Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer

por Stein, Alexander, Atanackovic, Djordje, Hildebrandt, Bert, Stübs, Patrick, Brugger, Wolfram, Hapke, Gunnar, Steffens, Claus-Christoph, Illerhaus, Gerald, Bluemner, Ernst, Stöhlmacher, Jan, Bokemeyer, Carsten
Publicado 2015

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

por Rowland, A, Dias, M M, Wiese, M D, Kichenadasse, G, McKinnon, R A, Karapetis, C S, Sorich, M J
Publicado 2015

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection

por Schirripa, M, Bergamo, F, Cremolini, C, Casagrande, M, Lonardi, S, Aprile, G, Yang, D, Marmorino, F, Pasquini, G, Sensi, E, Lupi, C, De Maglio, G, Borrelli, N, Pizzolitto, S, Fasola, G, Bertorelle, R, Rugge, M, Fontanini, G, Zagonel, V, Loupakis, F, Falcone, A
Publicado 2015

Long-term adverse outcomes in survivors of childhood bone sarcoma: the British Childhood Cancer Survivor Study

por Fidler, M M, Frobisher, C, Guha, J, Wong, K, Kelly, J, Winter, D L, Sugden, E, Duncan, R, Whelan, J, Reulen, R C, Hawkins, M M
Publicado 2015

Texture analysis of (125)I-A5B7 anti-CEA antibody SPECT differentiates metastatic colorectal cancer model phenotypes and anti-vascular therapy response

por Rajkumar, V, Goh, V, Siddique, M, Robson, M, Boxer, G, Pedley, R B, Cook, G J R
Publicado 2015

Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area

por Sideras, K, Bots, S J, Biermann, K, Sprengers, D, Polak, W G, IJzermans, J N M, de Man, R A, Pan, Q, Sleijfer, S, Bruno, M J, Kwekkeboom, J
Publicado 2015

Circulating cell-free miRNAs as biomarker for triple-negative breast cancer

por Shin, V Y, Siu, J M, Cheuk, I, Ng, E K O, Kwong, A
Publicado 2015

Modification of N staging systems for penile cancer: a more precise prediction of prognosis

por Li, Z-S, Yao, K, Chen, P, Wang, B, Chen, J-P, Mi, Q-W, Li, Y-H, Liu, Z-W, Qin, Z-K, Zhou, F-J, Han, H
Publicado 2015

(18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer

por You, J J, Cline, K J, Gu, C-S, Pritchard, K I, Dayes, I S, Gulenchyn, K Y, Inculet, R I, Dhesy-Thind, S K, Freeman, M A, Chan, A M, Julian, J A, Levine, M N
Publicado 2015

MiR-320e is a novel prognostic biomarker in colorectal cancer

por Perez-Carbonell, L, Sinicrope, F A, Alberts, S R, Oberg, A L, Balaguer, F, Castells, A, Boland, C R, Goel, A
Publicado 2015

Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study

por Wang, L L, Teshiba, R, Ikegaki, N, Tang, X X, Naranjo, A, London, W B, Hogarty, M D, Gastier-Foster, J M, Look, A T, Park, J R, Maris, J M, Cohn, S L, Seeger, R C, Asgharzadeh, S, Shimada, H
Publicado 2015

Circulating microRNAs as prognostic therapy biomarkers in head and neck cancer patients

por Summerer, I, Unger, K, Braselmann, H, Schuettrumpf, L, Maihoefer, C, Baumeister, P, Kirchner, T, Niyazi, M, Sage, E, Specht, H M, Multhoff, G, Moertl, S, Belka, C, Zitzelsberger, H
Publicado 2015

Background risk of breast cancer influences the association between alcohol consumption and mammographic density

por Trinh, T, Christensen, S E, Brand, J S, Cuzick, J, Czene, K, Sjölander, A, Bälter, K, Hall, P
Publicado 2015

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma

por Gore, M E, Szczylik, C, Porta, C, Bracarda, S, Bjarnason, G A, Oudard, S, Lee, S-H, Haanen, J, Castellano, D, Vrdoljak, E, Schöffski, P, Mainwaring, P, Hawkins, R E, Crinò, L, Kim, T M, Carteni, G, Eberhardt, W E E, Zhang, K, Fly, K, Matczak, E, Lechuga, M J, Hariharan, S, Bukowski, R
Publicado 2015

Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer

por Rees, J, Hurt, C N, Gollins, S, Mukherjee, S, Maughan, T, Falk, S J, Staffurth, J, Ray, R, Bashir, N, Geh, J I, Cunningham, D, Roy, R, Bridgewater, J, Griffiths, G, Nixon, L S, Blazeby, J M, Crosby, T
Publicado 2015

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases

por Renaud, Stéphane, Falcoz, Pierre-Emmanuel, Schaëffer, Mickaël, Guenot, Dominique, Romain, Benoit, Olland, Anne, Reeb, Jérémie, Santelmo, Nicola, Chenard, Marie-Pierre, Legrain, Michèle, Voegeli, Anne-Claire, Beau-Faller, Michèle, Massard, Gilbert
Publicado 2015

Postmenopausal mammographic breast density and subsequent breast cancer risk according to selected tissue markers

por Yaghjyan, Lusine, Pettersson, Andreas, Colditz, Graham A, Collins, Laura C, Schnitt, Stuart J, Beck, Andrew H, Rosner, Bernard, Vachon, Celine, Tamimi, Rulla M
Publicado 2015

Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma

por Rossi, L, Laas, E, Mallon, P, Vincent-Salomon, A, Guinebretiere, J-M, Lerebours, F, Rouzier, R, Pierga, J-Y, Reyal, F
Publicado 2015

Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting

por Lambrechts, Diether, Thienpont, Bernard, Thuillier, Vincent, Sagaert, Xavier, Moisse, Matthieu, Peuteman, Gilian, Pericay, Carles, Folprecht, Gunnar, Zalcberg, John, Zilocchi, Chiara, Margherini, Emmanuelle, Chiron, Marielle, Van Cutsem, Eric
Publicado 2015

How should individual participant data (IPD) from publicly funded clinical trials be shared?

por Tudur Smith, C., Hopkins, C., Sydes, M. R., Woolfall, K., Clarke, M., Murray, G., Williamson, P.
Publicado 2015